It has also been shown that fingolimod mitigates cancer-induced bone pain and neuroinflammation in mice (Grenald et al., 2017) and alleviates bortezomib-induced neuropathic pain in rats by S1PR1 antagonism (Stockstill et al., 2018). Here, S1PR1 is linked to cancer.